FFA
ABBV icon

Freedman Financial Associates’s AbbVie ABBV Stock Holding History

Freedman Financial Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-760
Closed -$123K – 4
2022
Q1 		$123K Buy
760
+102
+16% +$14.8K 0.08% 108
2021
Q4 		$89K Buy
658
+2
+0.3% +$236 0.06% 132
2021
Q3 		$71K Buy
656
+46
+8% +$5.26K 0.05% 152
2021
Q2 		$69K Buy
610
+2
+0.3% +$225 0.05% 151
2021
Q1 		$66K Buy
608
+2
+0.3% +$214 0.05% 158
2020
Q4 		$65K Buy
+606
New +$58.2K 0.06% 144

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Freedman Financial Associates's ABBV Position: Q2 2022 in Review

Freedman Financial Associates sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 760 shares — an estimated $123K sold.

Freedman Financial Associates first reported a position in ABBV in Q4 2020 and held it in 6 quarters. The position peaked at $123K in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Freedman Financial Associates reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
  • Freedman Financial Associates sold 760 AbbVie shares in Q2 2022, an estimated $123K.
  • Freedman Financial Associates first reported a position in AbbVie in Q4 2020 and held it in 6 quarters.
  • Freedman Financial Associates's AbbVie position peaked at $123K in Q1 2022.
  • 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Freedman Financial Associates's 13F filing for Q2 2022.